Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.
Name:
art%3A10.1186%2Fs12885-016-282 ...
Size:
610.9Kb
Format:
PDF
Description:
Open access full text article
Authors
Propper, DJones, K
Anthoney, D
Mansoor, Was
Ford, D
Eatock, M
Agarwal, R
Inatani, M
Saito, T
Abe, M
Evans, T
Affiliation
Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, Lower Ground Floor, Old Anatomy Building, Charterhouse Square, London, UKIssue Date
2016-10-10
Metadata
Show full item recordAbstract
TP300, a recently developed synthetic camptothecin analogue, is a highly selective topoisomerase I inhibitor. A phase I study showed good safety and tolerability. As camptothecins have proven active in oesophago-gastric adenocarcinomas, in this phase II study we assessed the efficacy and safety of TP300 in patients with gastric or gastro-oesophageal junction (GOJ) adenocarcinomas.Citation
Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. 2016, 16 (1):779 BMC CancerJournal
BMC CancerDOI
10.1186/s12885-016-2828-6PubMed ID
27724887Type
ArticleLanguage
enISSN
1471-2407ae974a485f413a2113503eed53cd6c53
10.1186/s12885-016-2828-6
Scopus Count
Collections
Related articles
- A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
- Authors: Evans TR, Pentheroudakis G, Paul J, McInnes A, Blackie R, Raby N, Morrison R, Fullarton GM, Soukop M, McDonald AC
- Issue date: 2002 Sep
- Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
- Authors: Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D
- Issue date: 2017 Nov
- Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
- Authors: Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I
- Issue date: 2019 Aug
- A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
- Authors: Scott LC, Yao JC, Benson AB 3rd, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR
- Issue date: 2009 Jan
- Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
- Authors: Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA
- Issue date: 2007 Mar